145 related articles for article (PubMed ID: 37156580)
21. Economic burden in patients with ALK + non-small cell lung cancer, with or without brain metastases, receiving second-line anaplastic lymphoma kinase (ALK) inhibitors.
Lin HM; Pan X; Hou P; Huang H; Wu Y; Ren K; Jahanzeb M
J Med Econ; 2020 Aug; 23(8):894-901. PubMed ID: 32347754
[No Abstract] [Full Text] [Related]
22. Incidence of skeletal-related events in patients with breast or prostate cancer-induced bone metastasis or multiple myeloma: A 12-year longitudinal nationwide healthcare database study.
Baek YH; Jeon HL; Oh IS; Yang H; Park J; Shin JY
Cancer Epidemiol; 2019 Aug; 61():104-110. PubMed ID: 31176960
[TBL] [Abstract][Full Text] [Related]
23. Association of Performance Status With Survival in Patients With Advanced Non-Small Cell Lung Cancer Treated With Pembrolizumab Monotherapy.
Sehgal K; Gill RR; Widick P; Bindal P; McDonald DC; Shea M; Rangachari D; Costa DB
JAMA Netw Open; 2021 Feb; 4(2):e2037120. PubMed ID: 33570575
[TBL] [Abstract][Full Text] [Related]
24. A study of non small cell lung cancer (NSCLC) patients with brain metastasis: A single centre experience.
Hatton N; Samuel R; Riaz M; Johnson C; Cheeseman SL; Snee M
Cancer Treat Res Commun; 2023; 34():100673. PubMed ID: 36603538
[TBL] [Abstract][Full Text] [Related]
25. Treatment dynamics of bone-targeting agents among men with bone metastases from prostate cancer in the United States.
Butler AM; Cetin K; Hernandez RK; Diane Reams B; Overman RA; I Kim J; Hirsch BR; Abernethy AP; Liede A; Alan Brookhart M
Pharmacoepidemiol Drug Saf; 2018 Feb; 27(2):229-238. PubMed ID: 29316026
[TBL] [Abstract][Full Text] [Related]
26. Real-world utilization of EGFR TKIs and prognostic factors for survival in EGFR-mutated non-small cell lung cancer patients with brain metastases.
Yu X; Sheng J; Pan G; Fan Y
Int J Cancer; 2021 Sep; 149(5):1121-1128. PubMed ID: 33970485
[TBL] [Abstract][Full Text] [Related]
27. Bone-targeting agents in major solid tumour metastases: a multinational cohort study.
Kim JH; Shen CY; Au PC; Baek YH; Cheung CL; Chung WP; Kleinman NJ; Lam TC; Liao TC; Lin TC; Shin JY; Sing CW; Wong ICK; Lai EC
BMJ Support Palliat Care; 2024 Jan; 13(e3):e1064-e1073. PubMed ID: 35177433
[TBL] [Abstract][Full Text] [Related]
28. More advantages in detecting bone and soft tissue metastases from prostate cancer using
Pianou NK; Stavrou PZ; Vlontzou E; Rondogianni P; Exarhos DN; Datseris IE
Hell J Nucl Med; 2019; 22(1):6-9. PubMed ID: 30843003
[TBL] [Abstract][Full Text] [Related]
29. Risk factors, prognostic factors, and nomograms for bone metastasis in patients with newly diagnosed infiltrating duct carcinoma of the breast: a population-based study.
Huang Z; Hu C; Liu K; Yuan L; Li Y; Zhao C; Hu C
BMC Cancer; 2020 Nov; 20(1):1145. PubMed ID: 33238981
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of PD-1/L1 inhibitors in brain metastases of non-small-cell lung cancer: pooled analysis from seven randomized controlled trials.
Li W; Jiang J; Huang L; Long F
Future Oncol; 2022 Jan; 18(3):403-412. PubMed ID: 34787500
[TBL] [Abstract][Full Text] [Related]
31. Skeletal related events in patients with bone metastasis arising from non-small cell lung cancer.
da Silva GT; Bergmann A; Thuler LCS
Support Care Cancer; 2016 Feb; 24(2):731-736. PubMed ID: 26143039
[TBL] [Abstract][Full Text] [Related]
32. Metastatic bone disease: Pathogenesis and therapeutic options: Up-date on bone metastasis management.
D'Oronzo S; Coleman R; Brown J; Silvestris F
J Bone Oncol; 2019 Apr; 15():004-4. PubMed ID: 30937279
[TBL] [Abstract][Full Text] [Related]
33. Targeted Therapies and Utility of the Lung-molGPA in Non-Small-Cell Lung Cancer Patients with Brain Metastases.
Cacho-Díaz B; Cuapantécatl LD; Garcilazo-Reyes YJ; Cabrera-Miranda L; Hernandez-Martinez JM; Arrieta O
Oncology; 2022; 100(10):542-554. PubMed ID: 35988535
[TBL] [Abstract][Full Text] [Related]
34. Post-progression outcomes of NSCLC patients with PD-L1 expression ≥ 50% receiving first-line single-agent pembrolizumab in a large multicentre real-world study.
Cortellini A; Cannita K; Tiseo M; Cortinovis DL; Aerts JGJV; Baldessari C; Giusti R; Ferrara MG; D'Argento E; Grossi F; Guida A; Berardi R; Morabito A; Genova C; Antonuzzo L; Mazzoni F; De Toma A; Signorelli D; Gelibter A; Targato G; Rastelli F; Chiari R; Rocco D; Gori S; De Tursi M; Mansueto G; Zoratto F; Filetti M; Bracarda S; Citarella F; Russano M; Cantini L; Nigro O; Buti S; Minuti G; Landi L; Ricciardi S; Migliorino MR; Natalizio S; Simona C; De Filippis M; Metro G; Adamo V; Russo A; Spinelli GP; Di Maio M; Banna GL; Friedlaender A; Addeo A; Pinato DJ; Ficorella C; Porzio G
Eur J Cancer; 2021 May; 148():24-35. PubMed ID: 33721704
[TBL] [Abstract][Full Text] [Related]
35. The presentation of brain metastases in melanoma, non-small cell lung cancer, and breast cancer and potential implications for screening brain MRIs.
Mills MN; Potluri TK; Kawahara Y; Fahey M; Figura NB; Soyano AE; Washington IR; Diaz R; Oliver DE; Yu HM; Etame AB; Vogelbaum MA; Czerniecki BJ; Arrington JA; Sahebjam S; Forsyth PA; Soliman HH; Han HS; Ahmed KA
Breast Cancer Res Treat; 2022 Jan; 191(1):209-217. PubMed ID: 34669082
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of denosumab vs zoledronic acid for prevention of skeletal-related events in patients with solid tumors and bone metastases in the United States.
Stopeck A; Rader M; Henry D; Danese M; Halperin M; Cong Z; Qian Y; Dansey R; Chung K
J Med Econ; 2012; 15(4):712-23. PubMed ID: 22409231
[TBL] [Abstract][Full Text] [Related]
37. Impact of the homogeneous and heterogeneous risk factors on the incidence and survival outcome of bone metastasis in NSCLC patients.
Song Q; Shang J; Zhang C; Zhang L; Wu X
J Cancer Res Clin Oncol; 2019 Mar; 145(3):737-746. PubMed ID: 30603904
[TBL] [Abstract][Full Text] [Related]
38. Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States.
Hernandez RK; Wade SW; Reich A; Pirolli M; Liede A; Lyman GH
BMC Cancer; 2018 Jan; 18(1):44. PubMed ID: 29306325
[TBL] [Abstract][Full Text] [Related]
39. Efficacy and safety of biweekly i.v. administrations of the Aurora kinase inhibitor danusertib hydrochloride in independent cohorts of patients with advanced or metastatic breast, ovarian, colorectal, pancreatic, small-cell and non-small-cell lung cancer: a multi-tumour, multi-institutional phase II study.
Schöffski P; Besse B; Gauler T; de Jonge MJ; Scambia G; Santoro A; Davite C; Jannuzzo MG; Petroccione A; Delord JP
Ann Oncol; 2015 Mar; 26(3):598-607. PubMed ID: 25488684
[TBL] [Abstract][Full Text] [Related]
40. Gender differences in persistency to bisphosphonates in patients with metastatic breast and prostate cancer.
Hadji P; Kyvernitakis J; Albert U; Jockwig J; Kostev K
Int J Clin Pharmacol Ther; 2014 May; 52(5):352-9. PubMed ID: 24691062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
